WHENOctober 06, 2012 @ 8:00am - 5:00pm
Date: Oct 06, 2012
Type: Association Events
Organizer: SABPA
Location: Institute of Americas, UCSD
Source: SABPA

When: 8:30 am – 5:00 pm, Saturday, October 6, 2012

Where:Institute of Americas, UCSD


Speaker presentation slides:


[nggallery id=5]


$20 for early birds by Oct. 1, $50 onsite registration (cash or check onsite); $10 off for students and postdocs. Fees include program

brochure, continental breakfast, coffee breaks, lunch and onsite reception. Online registration closes on Oct. 3.


Event Program

8:30 am Breakfast and Registration

8:50 am Opening Remarks

Peter Zhu, President, SABPA, San Diego Chapter

Yung-Chih Wang, Ph.D., MBA, Chair, Pacific Alliance Committee, SABPA; VP, Corporate Development, China, HUYA Bioscience International

9:00 am Enhancing the Pharmaceutical Innovative Engine through Strategic Outsourcing and Partnerships

Valeria Fantin, Ph.D., Vice President, Tumor Cell Biology, Pfizer

9:30 am Drug discovery in the New Era: Winning Global Competition

JinZi Wu, Ph.D., President & CEO, Ascletis, Inc.

10:00 am Perspectives of Global Partnerships for Drug Discovery and Development

Richard Soll, Ph.D., Senior VP of Integrated Services and Head of Corporate Alliances, WuXi AppTec

10:30 am Coffee Break

10:45 am Passion, Innovation and Execution–the Driving Forces of Novel Biotech Enterprises

Guo-Liang Yu, Ph.D., President & CEO, Epitomics Inc

11:15 am Panel Discussion:Effective Integration of External Rescources for Pharmaceutical Innovation

Session Leader:

  • Bill Christiansen, Partner, Cooley LLP

Panel Speakers:

  • Chunlin Chen,Ph.D., CEO of Shanghai Medicilon
  • Dana Hu-Lowe,Ph.D., VP and Head of Translational and Clinical Sciences of Shanghai ChemPartner Co.
  • Brian Maron, Site Executive Director, Covance
  • David Miao,Ph.D., CSO,Concortis Biosystems Corp.
  • Peng Wang, Ph.D., Director of Chemistry, Hamari Chemicals USA SDRC

12:15 pm Lunch

1:20 pm Opening of Afternoon Sessions

Stephanie Shi, Ph.D., Co-Chair, Pacific Alliance, SABPA; Integrated Sourcing Lead, External Research Solutions, Pfizer

1:30 pm Creating Pockets of Innovation in China

John Oyler, Founder & CEO, Beigene

2:00 pm A Decade of Changes and Opportunities: One Returnee’s Experiences for Biomedical Research in China

Hongkui Deng, Ph.D., Professor Cell Biology and Genetics, Beijing University

2:30 pm Impacting the Bottom Line: The Evolving Economics of Pharmaceutical Research and Commercial Information

Tim Hoctor, Commercial Director, Elsevier

3:00 pm Coffee Break

3:20 pm Panel Discussion: Leveraging Cross-Pacific Investment in Life Sciences

Session Leader:Paul Grayson, CEO, Anaphore

Panel Speakers:

Karl Handelsman, Managing Director, Life Sciences, CMEA Capital

James Huang, Managing Partner, Kleiner Perkins Caufield & Byers China, Shanghai, China

Andrew Wiseman, Ph.D. Corporate Business Development Officer, UC San Diego

Guo-Liang Yu, Ph.D., President & CEO, Epitomics Inc.

4:20 pm Introduction to Dongguan Songshan Lake Hi-Tech Industrial Development Zone (??????????????)

Song Tao, Consultant of Dongguan Municipal Government

4:50 pm Closing Remarks

Mingzhu Zhang, Ph.D., Executive VP, SABPA; VP of Business Development, Shanghai Medicilon

5:00 pm Close of Forum


Speaker Bio:


Chunlin Chen,Ph.D., CEO of Shanghai Medicilon

Dr. Chunlin Chen got his Ph.D. in Pharmacology and Toxicology from Oklahoma State University in 1994 and postdoctoral training in Pharmaceutical Department of St. Jude Children’s Research Hospital. During 1997-2002, Dr. Chen served as a Director of Pharmaceutical Department at Parker Hughes Cancer Center, Parker Hughes Institute. In 2002, Dr. Chen joined Vertex Pharmaceuticals as a Staff Investigator at Department of Pharmacokinetics and Metabolism, Non-clinical Drug Evaluation Division at Cambridge. He managed pre-clinical drug evaluation team and led to three IND filings approved by FDA.

Dr. Chen is the CEO and founder of Shanghai Medicilon, a pharmaceutical research and development CRO, located at Zhanjiang High-Tech Park and Chuansha Economic Park in Pudong, Shanghai. Medicilon’s core business is to provide chemistry, ADME, pharmacology, toxicology, biology and structural biology services to biotech and pharmaceutical companies all over the world.

Dr. Chen has over 80 publications in the field of drug discovery and development. Dr. Chen got several awards including Research Excellent Award from Oklahoma State University, Excellent Returnee Award from Shanghai and 1000-elite Program award from Chinese government. Dr. Chen currently serves as Associate Director for Drug Metabolism Section of Shanghai Pharmacology Society, Board Member for Pudong Biopharmaceutical Association.


Bill Christiansen,Partner, Cooley LLP

Dr. Bill Christiansen, Partner in thePatent Counseling & Prosecutionpractice at Cooley LLP, advises pharmaceutical, biotechnology and medical device companies, as well as universities, non-profit research institutions and investors, with respect to complex intellectual property matters and market exclusivity strategies. He specializes in patent matters, with particular emphasis on worldwide patent procurement, strategic management of patent portfolios, investment due diligence, early stage company counseling, competitive patent position analysis, and intellectual property value creation. Dr. Christiansen also advises litigation teams on technical and patent specific issues. He regularly counsels national and international clients with regard to freedom to operate opinions, invalidity and non-infringement opinions, due diligence transactions, oppositions, and re-examination proceedings.

Dr. Christiansen received his BS in Biochemistry and Biophysics (with honors) from Oregon State University and a PhD in Biochemistry/Biophysics/Molecular Biology from the University of Notre Dame. Dr. Christiansen received a JD with honors from the University of Washington School of Law, where he was the Managing Articles and Essays Editor of thePacific Rim Law & Policy Journal. Dr. Christiansen is admitted to the Washington State Bar and registered to practice before the U.S. Patent and Trademark Office.


Valeria Fantin,Ph.D., Vice President, Tumor Cell Biology, Pfizer

Valeria Fantin is currently Vice President of Tumor Cell Biology at Pfizer. She received her PhD in Molecular and Cellular Biology from Dartmouth, where she worked on insulin and IGF1 signaling. She went on to do her postdoctoral training in the department of Genetics at Harvard Medical School. The focus on her research work was breast cancer, and in particular in oncogene-driven metabolic rewiring. Prior to joining Pfizer, Valeria held positions at Merck, Ariad Pharmaceuticals and Agios Pharmaceuticals leading target validation as well as drug discovery and development projects in diverse areas including signal transduction, epigenetics and cancer metabolism.



Paul A. Grayson,CEO, Anaphore

Mr. Grayson has served as President and CEO of the company through its strategic re-positioning starting in June of 2011. He previously served as CEO of Fate Therapeutics, a San Diego-based, privately held biopharmaceutical company. Before that, he was managing director of Sanderling Ventures where he was a founding board member of multiple portfolio companies including: Calcimedica, Taligen Therapeutics (acquired by Alexion Pharmaceuticals), and Naviscan. Prior to Sanderling, Mr. Grayson served as the founding President and CEO of Senomyx Inc. [NASDAQ: SNMX] and part of the founding management team of Aurora Biosciences (acquired by Vertex). He received his M.B.A. from the University of California, Irvine, and his B.A. in Computer Science and Biochemistry from the University of California, Los Angeles.


Karl D. Handelsman,Managing Director, Life Sciences, CMEA Capital

Karl Handelsman joined CMEA Capital in 1999. Karl has been involved with numerous CMEA investments such as: Ambrx, Ensemble Therapeutics, Ilypsa, Intellikine, Kalypsys, Maxygen, Phenomix, Rigel, Syrrx, Tetraphase, and Xenoport. Prior to joining CMEA, Karl was one of the first employees of Tularik, Inc., a drug discovery company, where his business development role spanned corporate partnering, technology licensing, and operations. Karl was also one of the first employees of Whitehead Institute, a premier research organization within Massachusetts Institute of Technology (MIT); and he worked in business development at Millennium Pharmaceuticals. Karl holds graduate degrees from both MIT and Harvard Medical School.



James Huang,Managing Director, Life Sciences, CMEA Capital

James Huang, managing partner of KPCB China. James joined Kleiner Perkins Caufield & Byers China as a managing partner in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. James has made more than 10 investments in China since 2007.

Before coming to KPCB China, James was a managing partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. While at Vivo, James led numerous investments in China. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson).

James is Chairman of Board at Kindstar Global and Director at GenScript, Chiral Quest, Zenesis and CVie Therapeutics.

James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.


Dana Hu-Lowe,
Ph.D., VP and Head of Translational and Clinical Sciences of Shanghai ChemPartner Co.

Dr. Dana Hu-Lowe is the Vice President and Head of Translational and Clinical Sciences of Shanghai ChemPartner Co. Ltd.. Her role has been to strategically and scientifically position ChemPartner and build alliances and partnership with industry and academic centers with the goal to effectively enhance clinical research and personalized medicine through the CRO business model. Previously, Dr. Hu-Lowe was a Group Leader (the Angiogenesis and Tumor Microenvironment Program), Research Project Leader and Associate Research Fellow at Pfizer Oncology Research Unit. Dr. Hu-Lowe has an extensive drug R&D experience and was instrumental in the discovery, research, development and commercialization of Inlyta (axitinib). She was also responsible for the advancement of several additional oncology projects (small molecules and biologics) to clinical Development. Equally significantly, Dr. Hu-Lowe played a key role in bridging and integrating components of Research and Clinical Development, which enabled early and better decision-making for a number of projects. Her sustained accomplishments at Pfizer earned her many awards including the Pfizer Career Achievement Award in 2007. Dr. Hu-Lowe received her Ph.D. degree in Biochemistry from Univ. of Mississippi and underwent postdoctoral training at the Scripps Research Institute and the Burnham Cancer Institute (now the Sanford-Burnham Medical Research Institute) in the Cell Adhesion and Extracellular Matrix Program.


Tim Hoctor,Commercial Director, Elsevier

Tim Hoctor is Commercial Director for Elsevier’s Chemistry and Life Science Product Group. He has been with Elsevier for 14 years, and prior to that, worked in technical positions at data technology companies including Netscape, Oracle (Vantive), and Sun Microsystems. He holds a bachelor’s degree from University of Southern California, and has completed graduate programs at Stanford and MIT.






Brian Maron,Site Executive Director, Covance

Mr. Maron is responsible for Early Development at the Covance facility in Shanghai, China. Previously, Brian was responsible for Toxicology Operations at the Chandler, Arizona facility. He is responsible for implementing work standards and leadership at the site. He is responsible for study direction, pathology, DMPK, animal operations, laboratory operations, and dose formulations. He is responsible for ensuring that studies comply with appropriate standard operating procedures (SOPs), Good Laboratory Practices (GLPs), AAALAC International, Animal Welfare Act, and regulatory agency guidelines. He was previously the chairperson of the Chandler IACUC. He is responsible for performance management of the staff as well as fiscal management of the operation. He is responsible for on-time delivery of high quality results to both internal and external clients.

Mr. Maron has over 17 years of pre-clinical and clinical Drug Development Experience at Covance. He has worked for Covance in Milwaukee, WI; Reno, NV, London, United Kingdom, and Chandler, AZ.


David Miao,Ph.D., CSO, Concortis Biosystems Corp.

David Miao, Ph.D., is Chief Scientific Officer (CSO) and a founder of Concortis Biosystems Corp, an ADC (antibody-drug conjugate) specialty company created to facilitate the development of next generation antibody-based therapeutics. As CSO, Dr. Miao is responsible for the management of Concortis’ internal R&D and global collaborations, including strategic planning, project management, budgeting and resource allocation. Dr. Miao joined Concortis in 2011 bringing in more than 10 years of biotech experiences in both small molecule and biological drug discovery. Prior to Concortis, Dr. Miao was the Director of Chemistry and a member of the Senior R&D Team at Ambrx Inc., where he led chemistry research. Prior to Ambrx, Dr. Miao was a Principal Scientist at Enanta Pharmaceuticals, where he led and was involved in several drug discovery programs that lead to a phase III clinical trials now. Dr. Miao holds a B.S. in chemistry from Nankai University and a Ph.D. in chemistry from Peking University. He conducted his post-doctorate research at the Medical Center of Vanderbilt University.

John V. Oyler,Founder & CEO, Beigene

John is a serial entrepreneur with a track record of success. John has raised over $270 million in capital, each round providing positive returns. John is most known for building highly functional, passionate and world-class organizations.

Currently, John is Founder& CEO of BeiGene. BeiGene is a Chinese life sciences biotechnology company based in Beijing that is focused on discovering and developing innovative oncology drugs that will address unmet medical needs in cancers that are prevalent in China and the Asia-Pacific region. It was founded by Dr. Xiaodong Wang, Head of The National Institute of Biologic Sciences in Beijing and Member of National Academy of Sciences, USA; Dr. Peter Ho, Former VP of Oncology Development at Johnson&Johnson; and Dr. Pearl Huang, Former VP Integrator and Head of Biomarker Discovery and Early Development Strategy for Oncology at Merck.

Jon has also started (or re-started, in the case of Genta), several companies including:

BioDuro (sold to PPD). 670+ person research company in Beijing that was a leader in its vision and ability to successfully undertake in fully integrated programs.

Galenea (private). 2003-2004. Drug discovery company developing drugs for CNS disease (schizophrenia) and respiratory disease (siRNA-based) partnered with Otsuka Pharmaceuticals in a $50 million deal.

Genta (Nasdaq-GNTA). 1997-1998. John served as co-CEO of this publicly company which later grew to a market capitalization of over $1.6 billion.

Telephia (sold). 1998-2002. John founded and co-managed this information services company for the telecommunications industry. Telephia was purchased by Nielsen for just under $500 million.

Mr. Oyler spent four years at McKinsey where he spent 1992-3 working in China and holds a BS from MIT and a MBA from Stanford.


Richard Soll,Ph.D., Senior VP of Integrated Services and Head of Corporate Alliances, WuXi AppTec

Dr. Richard M Soll is SVP, Integrated Services and Head of Corporate Alliances at WuXi AppTec, a Shanghai headquartered and New York Stock Exchange listed (NYSE: WX) premium provider of pharmaceutical R&D services across.In this capacity, Dr. Soll has advanced more than 30 programs across major target classes and therapeutic indications from hits into lead opitmization campaigns, giving rise to clinical candidates on behalf of WuXi customers in pharma and biotech. In addition, Dr. Soll heads Corporate Alliances Office at WuXi, oversees strategic partnering activities with our global partners in designing and executing creative collaboration models to maximize R&D productivity and shorten time to market.

Previously, WuXi, Dr. Richard Soll was CSO and VP, R&D at TargeGen where he led innovative clinical-stage R&D programs for isoform-specific PI3K inhibitors as therapeutics for inflammation, respiratory disease and cancer, muti-targeted src/VEGF inhibitors as the first topical kinase inhibitors AMD, and highly selective JAK2 inhibitors for the treatment of myeloproliferative disorders, the latter leading to the acquisition of TargeGen by Sanofir. Dr. Soll founded the chemistry department 3-DP as VP, Chemistry. Dr. Soll spent 10 years at Wyeth Pharmaceuticals, and trained as a synthetic chemist at Dartmouth and Harvard.

Dr. Soll’s drug discovery and development experiences has led to more than 7 drug candidates entering and advancing the clinic for infectious disease, cardiovascular disease, cancer, and ocular indications up to pivotal trials. Dr. Soll’s patent and publication record in peer reviewed journals has produced more than 100 patents and papers.

Dr. Soll has been an SAB member in biotech and advisor to entrepreneurs.


Tao Song,Consultant of Dongguan Municipal Government

Tao Song is currently a consultant of Dongguan municipal government and a technology development strategy consultant of Songshan Lake hi-tech industrial development zone. Before being invited to take his current position in 2009 by Wang Yang, the Party committee secretary of Guangdong Province, Mr. Tao Song was the Assistant to President of HeJian Technology (Suzhou) Co. Ltd. from 2003-2009. Mr. Tao Song was a teacher in National Chiao Tung University from 1998-2003.

Peng Wang,Ph.D., Director of Chemistry, Hamari Chemicals USA SDRC

Peng Wang, Ph.D., director of chemistry of Hamari Chemicals USA, San Diego Research Center. Hamari Chemicals is a global provider of custom chemical manufacturing to the pharmaceutical industry. Our San Diego Research Center specializes in custom synthesis, contract process research and development, and contract manufacture of APIs and advanced intermediate from mg to sub kg scale.

Peng obtained a B.S. degree in chemistry from Beijing University in 1984 and obtained a Ph.D. degree in organic chemistry (Professor Francis Johnson) from SUNY Stony Brook in 1990. He studied with Professor Harry Wasserman at Yale University as a post-doctoral associate from 1989 to 1991.

Peng started his industrial career at Boehringer Ingelheim as a post-doctoral associate working with Dr. Julian Adams. Thereafter, he worked at Organix Inc., Scriptgen Pharmaceuticals, Millennium Pharmaceuticals, Neurocrine Biosciences, and Phenomix Corporation with increased responsibility before joining Hamari in late 2011.

Jinzi Wu,Ph.D., President & CEO, Ascletis, Inc.

Dr. Jinzi J. Wu is Co-founder, Chairman, President and CEO, Ascletis, Inc. He successfully completed $100M Series A financing in 2011, including a first tranche of $50M. He has assembled world-class team and investors to deliver the Company’s two pronged business strategy: near-term accelerated revenue generation and long-term value creation. Prior to founding Ascletis, Dr. Wu was Vice President, HIV drug discovery performance unit and Head of infectious disease Discovery DMPK at GSK. He oversaw the global HIV drug discovery from target identification and lead optimization to the preclinical and clinical development. Over the last two years (2009 and 2010), under Dr. Wu’s leadership, his Unit delivered two phase II clinical drugs with the best-in-class potential and one phase I asset. Prior to his joining GSK in June, 2008, Dr. Wu was Vice President, Preclinical and Basic Research from 2004-2008 at Ambrilia Biopharma, a biopharmaceutical company devoted to the development of anti-viral drugs. From 1992-2004, he held senior positions, with increasing responsibilities, at Biotech and Big Pharma including Immunex (now Amgen), Novartis and Hoechst Marion Roussel (now Sanofi-Aventis). Dr. Wu has published over 30 peer-reviewed articles and book chapters in prestigious journals and books. He is a co-inventor of a number of patent applications. Dr. Wu received his PhD in Cancer Biology from the University of Arizona.

Andrew Wiseman,Ph.D. Corporate Business Development Officer, UC San Diego

Andrew Wiseman, PhD, Corporate Business Development Officer in UC San Diego Health Sciences in University of California San Diego. Dr. Wiseman brings more than 30 years of experience in the biotechnology industry and academic research and has spent more than 20 years building and leading business development programs.

Dr. Wiseman was a founder and Head of Business Development and Investor Relations at La Jolla Pharmaceutical Company where he also was responsible for key opinion leader and patient advocacy development in support of the Company’s efforts to bring the first drug to patients with systemic lupus erythematosus. He was a key player in the Company’s successful efforts to raise approximately $350 million through partnering and equity financings in support of its product development activities. Prior to founding La Jolla Pharmaceutical, he worked in business development, product development and marketing at Quidel, an immunodiagnostics company.

Before joining the biotechnology industry, Dr. Wiseman was an Assistant Professor in the Department of Cell Biology at the Research Institute of Scripps Clinic in La Jolla California. He has a Ph.D. in Genetics, Cell and Molecular Biology from Duke University in Durham North Carolina and was a Helen Hay Whitney Post-Doctoral Fellow at the California Institute of Technology in Pasadena California working on mitochondrial biogenesis with Giuseppe Attardi, who was a member of the National Academy of Sciences.

Guo-Liang Yu,Ph.D., President & CEO, Epitomics Inc.

Dr. Guo-Liang Yu is the President and CEO of Epitomics Inc., an emerging biotech company with 320 employees dedicated to the development of innovative monoclonal antibodies for discovery, diagnostics and therapeutics. He co-founded Epitomics in 2001. Epitomic is headquartered in the San Francisco Bay Area and has a wholly owned subsidiary in Hangzhou, China.

Dr. Guo-Liang Yu was Senior Vice-President of Research and Development at Mendel Biotechnology Inc., where his team analyzed the function of a complete set of plant transcription factors by knock-out and over-expression in planta. Guo-Liang was a Senior Scientist at Human Genome Sciences Inc. where he discovered the target Blys for the lupus drug belimumab.

Guo-Liang was trained at Harvard Medical School as a postdoctoral fellow and earned a Ph.D. degree with Nobel Laureate Dr. Elizabeth Blackburn in Molecular Biology from the University of California, Berkeley and B.S. degree in Biochemistry from Fudan University in Shanghai.

Guo-Liang is a co-inventor of more than 250 patents and a co-author of 40 scientific articles. Guo-Liang is the founding president of Chinese Biopharmaceutical Association and services several professional organizations in the US and China as a member of the board of directors or board of advisory.